ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
Company nameADMA Biologics Inc
IPO dateOct 17, 2013
CEOMr. Adam S. Grossman
Number of employees677
Security typeOrdinary Share
Fiscal year-endOct 17
Address465 State Route 17
CityRAMSEY
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code07446
Phone12014785552
Websitehttps://www.admabiologics.com/
Ticker SymbolADMA
IPO dateOct 17, 2013
CEOMr. Adam S. Grossman
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data